Search

Your search keyword '"Larrey, Dominique"' showing total 964 results

Search Constraints

Start Over You searched for: Author "Larrey, Dominique" Remove constraint Author: "Larrey, Dominique"
964 results on '"Larrey, Dominique"'

Search Results

3. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort

4. SAT-306 Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury

7. Drug‐induced liver injury related to gene therapy: A new challenge to be managed.

8. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

9. RE: Praluent (Alirocumab)-Induced Renal Injury

11. Large-scale screening of lipase acid deficiency in at risk population

12. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

15. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

16. irLI or Not irLI: That is the Question

20. A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury

21. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

22. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen : The ANRS HC34 REVENGE Study

26. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs

27. Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study

28. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study

33. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

35. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study

36. ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts

38. Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension

40. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France

41. Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide

42. Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings

43. Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers

45. Relative Risks from Case-Population Data

46. Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury.

47. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

48. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)

49. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation

50. Impact of direct‐acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.

Catalog

Books, media, physical & digital resources